 However, patients receiving prolonged treatment courses often end up more disabled than they started.Despite these results from several landmark studies in the 1970s, in the 1980s pharmaceutical companies such as Eli Lily together with the American Psychiatric Association began more aggressively pushing second generation anti-depressants and anti-psychotics on psychiatric patients.Many prominent academic psychiatrists worked as key opinion leaders for the pharmaceutical companies, and were compensated millions of dollars.